Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeut...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Subramanya Hosahalli Nyavanandi Vijay Kumar Potluri Vijay Reddy Sanjeeva Nadipalli Prabhakara Rao Smith Roger A Panigrahi Sunil Kumar Thompson Scott K John Tyler M Sengupta Saumitra |
| description | The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9757382B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9757382B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9757382B23</originalsourceid><addsrcrecordid>eNrjZEgLLM3MS6zKz8nMSy1WSMxLUUisSixEEStWSClNzFHIzMvITMosyS8qVshPUwhyDNYPcnTT93X11ncN8gbrDPA09tZ39A7RDwhx9dPPDfEPUihILMkoT6ws5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8aHBluam5sYWRk5GxkQoAQCt0jxa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways</title><source>esp@cenet</source><creator>Subramanya Hosahalli ; Nyavanandi Vijay Kumar ; Potluri Vijay ; Reddy Sanjeeva ; Nadipalli Prabhakara Rao ; Smith Roger A ; Panigrahi Sunil Kumar ; Thompson Scott K ; John Tyler M ; Sengupta Saumitra</creator><creatorcontrib>Subramanya Hosahalli ; Nyavanandi Vijay Kumar ; Potluri Vijay ; Reddy Sanjeeva ; Nadipalli Prabhakara Rao ; Smith Roger A ; Panigrahi Sunil Kumar ; Thompson Scott K ; John Tyler M ; Sengupta Saumitra</creatorcontrib><description>The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170912&DB=EPODOC&CC=US&NR=9757382B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170912&DB=EPODOC&CC=US&NR=9757382B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Subramanya Hosahalli</creatorcontrib><creatorcontrib>Nyavanandi Vijay Kumar</creatorcontrib><creatorcontrib>Potluri Vijay</creatorcontrib><creatorcontrib>Reddy Sanjeeva</creatorcontrib><creatorcontrib>Nadipalli Prabhakara Rao</creatorcontrib><creatorcontrib>Smith Roger A</creatorcontrib><creatorcontrib>Panigrahi Sunil Kumar</creatorcontrib><creatorcontrib>Thompson Scott K</creatorcontrib><creatorcontrib>John Tyler M</creatorcontrib><creatorcontrib>Sengupta Saumitra</creatorcontrib><title>Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways</title><description>The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZEgLLM3MS6zKz8nMSy1WSMxLUUisSixEEStWSClNzFHIzMvITMosyS8qVshPUwhyDNYPcnTT93X11ncN8gbrDPA09tZ39A7RDwhx9dPPDfEPUihILMkoT6ws5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8aHBluam5sYWRk5GxkQoAQCt0jxa</recordid><startdate>20170912</startdate><enddate>20170912</enddate><creator>Subramanya Hosahalli</creator><creator>Nyavanandi Vijay Kumar</creator><creator>Potluri Vijay</creator><creator>Reddy Sanjeeva</creator><creator>Nadipalli Prabhakara Rao</creator><creator>Smith Roger A</creator><creator>Panigrahi Sunil Kumar</creator><creator>Thompson Scott K</creator><creator>John Tyler M</creator><creator>Sengupta Saumitra</creator><scope>EVB</scope></search><sort><creationdate>20170912</creationdate><title>Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways</title><author>Subramanya Hosahalli ; Nyavanandi Vijay Kumar ; Potluri Vijay ; Reddy Sanjeeva ; Nadipalli Prabhakara Rao ; Smith Roger A ; Panigrahi Sunil Kumar ; Thompson Scott K ; John Tyler M ; Sengupta Saumitra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9757382B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Subramanya Hosahalli</creatorcontrib><creatorcontrib>Nyavanandi Vijay Kumar</creatorcontrib><creatorcontrib>Potluri Vijay</creatorcontrib><creatorcontrib>Reddy Sanjeeva</creatorcontrib><creatorcontrib>Nadipalli Prabhakara Rao</creatorcontrib><creatorcontrib>Smith Roger A</creatorcontrib><creatorcontrib>Panigrahi Sunil Kumar</creatorcontrib><creatorcontrib>Thompson Scott K</creatorcontrib><creatorcontrib>John Tyler M</creatorcontrib><creatorcontrib>Sengupta Saumitra</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Subramanya Hosahalli</au><au>Nyavanandi Vijay Kumar</au><au>Potluri Vijay</au><au>Reddy Sanjeeva</au><au>Nadipalli Prabhakara Rao</au><au>Smith Roger A</au><au>Panigrahi Sunil Kumar</au><au>Thompson Scott K</au><au>John Tyler M</au><au>Sengupta Saumitra</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways</title><date>2017-09-12</date><risdate>2017</risdate><abstract>The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US9757382B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A52%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Subramanya%20Hosahalli&rft.date=2017-09-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9757382B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |